AROA BIOSURGERY LIMITED (ARX)
Share Price Analysis and Chart

Enter the company code or Name for stock analysis:

ARX - AROA BIOSURGERY LIMITED

FNArena Sector : Pharmaceuticals & Biotech/Lifesciences
Year End: March
GICS Industry Group : Pharmaceuticals, Biotechnology & Life Sciences
Debt/EBITDA: -7.25
Index: ALL-ORDS

LAST PRICE CHANGE +/- CHANGE % VOLUME

$0.51

18 Apr
2024

-0.010

OPEN

$0.53

-1.92%

HIGH

$0.54

100,009

LOW

$0.51

TARGET
$1.05 105.9% upside
OTHER COMPANIES IN THE SAME SECTOR
1AD . ACR . ACW . ADO . AFP . AGH . AVH . BIO . BOT . CSL . CUV . EOF . GSS . HXL . IDT . IMM . IMU . IVX . LGP . MAP . MDC . MSB . MVP . MYX . NEU . NXS . OCC . OPT . OSL . PAR . PBP . PER . PNV . PYC . RAC . RCE . SPL . TLX . TRP . VIT . ZNO .
FNARENA'S MARKET CONSENSUS FORECASTS
ARX: 1
Title FY24
Forecast		 FY25
Forecast
EPS (cps) - 1.6 xxx
DPS (cps) 0.0 xxx
EPS Growth N/A xxx
DPS Growth N/A xxx
PE Ratio N/A xxx
Dividend Yield 0.0% xxx
Div Pay Ratio(%) N/A xxx
This company reports in NZD.
All estimates have been converted into AUD by FNArena at present FX values.

Dividend yield today if purchased 3 years ago: 0.00%

DIVIDEND YIELD CALCULATOR

Dividend Yield Today On Last Actual Payout :

 0.00

Estimated Dividend Growth
(Average Of Past Three Years)

  %

Amount Invested

 $ 

Tell Me The Dividend After This Many Years
Past performance is no guarantee for the future. Investors should take into account that heavy swings in share price or exceptional circumstances (a la 2009) can have a significant impact on short term calculations and averages
HISTORICAL DATA ARE ALL IN AUD
Copyright © 2024 FactSet UK Limited. All rights reserved
Title 20192020202120222023
EPS Basic xxxxxxxxxxxx-0.1
DPS All xxxxxxxxxxxx0.0
Sales/Revenue xxxxxxxxxxxx57.7 M
Book Value Per Share xxxxxxxxxxxx27.7
Net Operating Cash Flow xxxxxxxxxxxx-3.4 M
Net Profit Margin xxxxxxxxxxxx-0.63 %

EPS Basic

DPS All

Sales/Revenue

Book Value Per Share

Net Operating Cash Flow

Net Profit Margin

Title 20192020202120222023
Return on Capital Employed xxxxxxxxxxxx-0.38 %
Return on Invested Capital xxxxxxxxxxxx-0.36 %
Return on Assets xxxxxxxxxxxx-0.34 %
Return on Equity xxxxxxxxxxxx-0.38 %
Return on Total Capital xxxxxxxxxxxx-4.41 %
Free Cash Flow ex dividends xxxxxxxxxxxx-8.9 M

Return on Capital Employed

Return on Invested Capital

Return on Assets

Return on Equity

Return on Total Capital

Free Cash Flow ex dividends

Title 20192020202120222023
Short-Term Debt xxxxxxxxxxxx1 M
Long Term Debt xxxxxxxxxxxx6 M
Total Debt xxxxxxxxxxxx7 M
Goodwill - Gross xxxxxxxxxxxx5 M
Cash & Equivalents - Generic xxxxxxxxxxxx43 M
Price To Book Value xxxxxxxxxxxx3.79

Short-Term Debt

Long Term Debt

Total Debt

Goodwill - Gross

Cash & Equivalents - Generic

Price To Book Value

Title 20192020202120222023
Capex xxxxxxxxxxxx6.9 M
Capex % of Sales xxxxxxxxxxxx12.01 %
Cost of Goods Sold xxxxxxxxxxxx10 M
Selling, General & Admin. Exp & Other xxxxxxxxxxxx53 M
Research & Development xxxxxxxxxxxx9 M
Investments - Total xxxxxxxxxxxx-

Capex

Capex % of Sales

Cost of Goods Sold

Selling, General & Admin. Exp & Other

Research & Development

Investments - Total

EXPERT VIEWS
Display All Commentary

Sentiment Indicator

1.0

No. Of Recommendations

2
BROKER DATE RATING RECOMMENDATION TARGET PRICE % TO REACH TARGET COMMENTARY

Morgans

xx/xx/xxxx

1

xxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

Bell Potter

31/01/2024

1

Buy

$0.90

76.47%

Aroa Biosurgery has downgraded its full year revenue guidance by -8%, now anticipating NZ$67-70m. As per Bell Potter, this represents 11% year-on-year top line growth at the midpoint, compared to the 55% growth achieved in the previous year.

Bell Potter explains the previously flagged de-stocking by its major US distribution partner commenced in the first half, driving a -13% decline in revenues, but revenues have continued to be weak as the distributor continues to reduce inventory.

The company expects this to be transitory and anticipates a return to growth in FY25.

The Buy rating is retained and the target price decreases to 90 cents from $1.15.

FORECAST
Bell Potter forecasts a full year FY24 dividend of 0.00 cents and EPS of minus -1.67 cents.
Bell Potter forecasts a full year FY25 dividend of 0.00 cents and EPS of 0.28 cents.
Access Stockbroker Research History >

ARX STOCK CHART

FNArena News on ARX

1
Australian Broker Call *Extra* Edition – Mar 28, 2024

Mar 28 2024 - Daily Market Reports
2
Rudi’s View: Selective Opportunities Among Discounted REITs

Mar 20 2024 - Rudi's View
3
In Case You Missed It – BC Extra Upgrades & Downgrades – 09-02-24

Feb 09 2024 - Weekly Reports
4
Australian Broker Call *Extra* Edition – Feb 07, 2024

Feb 07 2024 - Daily Market Reports
5
Australian Broker Call *Extra* Edition – Feb 06, 2024

Feb 06 2024 - Daily Market Reports

Latest Pharmaceuticals & Biotech/Lifesciences News

1
Dr Boreham’s Crucible: Race Oncology

Apr 09 2024 - Small Caps
2
The Power Of New Weight-Loss Drugs

Apr 03 2024 - International
3
Dr Boreham’s Crucible: Neuren Pharmaceuticals

Mar 11 2024 - Small Caps
4
Spotlight On ASX-Listed Cannabis Companies

Jan 31 2024 - Small Caps
5
Transformational Trial Results For Neuren Pharmaceuticals

Dec 20 2023 - Small Caps
6
Dr Boreham’s Crucible: Imugene

Dec 11 2023 - Small Caps
7
Dr Boreham’s Crucible: PYC Therapeutics

Nov 22 2023 - Small Caps
8
Dr Boreham’s Crucible: Paradigm Biopharmaceuticals

Nov 06 2023 - Small Caps
9
Dr Boreham’s Crucible: Argenica Therapeutics

Sep 28 2023 - Small Caps
10
Dr Boreham’s Crucible: Cleo Diagnostics

Aug 30 2023 - Small Caps